A Large-Scale Acquisition Is Unlikely for Pfizer Until This Happens
Pharma titan Pfizer (NYSE: PFE) announced second-quarter earnings on Tuesday, but the drugmaker's performance was clearly a secondary issue for analysts and investors alike. Despite beating consensus on adjusted earnings per share and improving its full-year outlook for this same metric, for example, the drugmaker's shares still ended the day down 0.24%.
Pfizer's respectable Q2 earnings release was overshadowed by its glaring need to execute a large-scale acquisition, as well as management's unexpected pivot to in-line market opportunities as the company's main near-term growth driver.
Image source: Getty Images.
Source: Fool.com
Pfizer Inc. Stock
€24.05
0.590%
The stock is one of the favorites of our community with 30 Buy predictions and 4 Sell predictions.
As a result the target price of 41 € shows a very positive potential of 70.51% compared to the current price of 24.05 € for Pfizer Inc..
